High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer
Biomolecules · 15.06.2023 · 13 (6) · 991
DOI: 10.3390/biom13060991 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 15.06.2023. Verfasst von Xia Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital, Sichuan University, Precision Medicine Key Laboratory of…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, West China Hospital, Sichuan University, Science and Technology Program of Sichuan.
Abstract (Originalsprache)
High tumour programmed cell death-ligand 1 (PD-L1) expression is associated with poor progression-free survival (PFS) after tyrosine kinase inhibitor (TKI) therapy in ALK-rearranged non-small cell lung cancer (NSCLC). However, the characteristics of the tumour microenvironment (TME) and their prognostic values in ALK-rearranged NSCLC are unknown. Here, we collected tumour tissues from pretreated ALK-rearranged NSCLC patients, immunohistochemical staining was used to assess PD-L1 expression, and tumour-infiltrating immune cells were determined via multiplex immunofluorescence staining (mIF). Our data showed that the median values of PFS for the high PD-L1 group and low PD-L1 group who received ALK-TKI treatment were 4.4 and 16.4 months, respectively (p = 0.008). The median overall survival (OS) of the two groups was 24.0 months and not reached, respectively (p = 0.021). Via univariate and multivariate analyses, a high PD-L1 expression and a worse ECOG PS were determined to be independent prognostic factors of OS (HR = 3.35, 95% CI: 1.23–9.11, p = 0.018; HR = 6.42, 95% CI: 1.45–28.44, p = 0.014, respectively). In addition, the high PD-L1 group had increased Tregs and exhausted CD8+ T cells in both the tumour and stroma (all p < 0.05). High PD-L1 expression was an adverse predictive and prognostic biomarker for ALK-rearranged NSCLC. The characteristics of the TME in patients with high PD-L1 expression were shown to have an immunosuppressive status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital, Sichuan University, Precision Medicine Key Laboratory of Sichuan Province, Chengdu 610041, China
Förderung
- National Natural Science Foundation of China
- West China Hospital, Sichuan University
- Science and Technology Program of Sichuan
- Major Science and Technology Innovation Project of Chengdu City
- Sichuan Provincial Department of Science and Technology
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Tian, X., Li, Y., Huang, Q., Zeng, H., Wei, Q., & Tian, P. (2023). High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer. Biomolecules, 13(6), 991. https://doi.org/10.3390/biom13060991
Vancouver
Tian X, Li Y, Huang Q, Zeng H, Wei Q, Tian P. High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer. Biomolecules. 2023;13(6):991. doi:10.3390/biom13060991
BibTeX
@article{Tian2023,
author = {Tian, Xia and Li, Yalun and Huang, Qin and Zeng, Hao and Wei, Qi and Tian, Panwen},
title = {High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {6},
pages = {991},
doi = {10.3390/biom13060991}
}
EUVIMED